Maze Therapeutics (MAZE) Stock: Buy, Sell, or Hold?
MAZE - Maze Therapeutics, Inc. Common Stock
$24.60
-0.22 (-0.89%)
▼
5d:
-4.91%
30d:
-10.64%
90d:
+2.12%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When MAZE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: MAZE shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: MAZE shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: MAZE is currently trading at $24.60, which is considered oversold relative to its 30-day fair value range of $26.10 to $29.10.
Technical Outlook: Technically, MAZE is in a uptrend. The price is currently testing key support at $23.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MAZE scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $62.55 (+154.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MAZE is in a uptrend. The price is currently testing key support at $23.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MAZE scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $62.55 (+154.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$26.10 -
$29.10
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 154.2% below Wall St target ($62.55)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$26.10 -
$29.10
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$23.94
Resistance Level
$28.46
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.75
Wall Street Target
$62.55
(+154.2%)
Share & Embed Analysis
Last updated: September 13, 2026 11:37 AM ET
Data refreshes hourly during market hours. Next update: 12:37 PM
Data refreshes hourly during market hours. Next update: 12:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MAZE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Harold Bernstein
SELL
15000 shares
2026-04-01
Amy Bachrodt
SELL
2500 shares
2026-04-01
Harold Bernstein
SELL
15000 shares
2026-03-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 47 HOLD |
